Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BORTEM 17
2024-515142-16-00Phase 2Authorised
- Sponsor
- Helse Bergen
- Start
- Oct 2024
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of bortezomib and temozolomide in glioma, glioblastoma (GBM) and astrocytoma, sponsored by Helse Bergen. Primary endpoints: Safety and tolerability of bortezomib administered with temozolomide (Phase Ib), Overall survival at 1 year (Phase II) and 4 more. Planned start Oct 2024; status: authorised.
02
Drugs
bortezomibtemozolomide
03
Conditions
gliomaglioblastoma (GBM)astrocytoma
Beyond the preview
Go deeper on 2024-515142-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515142-16-00.